FPT Proposes Public-Private Partnership Model to Develop Vietnam's Digital Healthcare Ecosystem
HANOI, Vietnam--(BUSINESS WIRE)--Jun 6, 2025--
Global IT services provider FPT and Pharma Group jointly hosted the Healthcare Innovation Forum - HIF 2025. The event served as a multi-stakeholder dialogue platform with a spotlight on breakthrough innovations in science, technology, and AI to accelerate healthcare advancements and drive digital transformation in public health services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606137635/en/
FPT Proposes Public-Private Partnership Model to Develop Vietnam's Digital Healthcare Ecosystem
The Forum was attended by Vietnam Deputy PM H.E. Le Thanh Long, key government officials, and international guests including U.S. Ambassador Marc Knapper, Swiss Ambassador Thomas Gass, former German Vice Chancellor Dr. Philipp Rösler, and representatives from Japan, Singapore, and Harvard Medical School.
Vietnam Deputy PM H.E. Le Thanh Long stressed the urgent need to reform healthcare, outlining five strategies: accelerate digitalization with AI and IoT; boost biotech research; strengthen the pharmaceutical sector; foster public–private partnerships; and expand international cooperation for a modern digital health system.
Mr. Darrell Oh, Chairman of Pharma Group, said: 'Pharma Group, representing the innovative pharmaceutical industry, reaffirms its commitment to supporting Vietnam in achieving the goals outlined in Vision 2045. Realizing this ambition requires a unified, multi-stakeholder approach. Only through sustained collaboration can policy be translated into impactful, lasting improvements in public health. Investing in healthcare is, ultimately, an investment in Vietnam's most vital asset: its people.'
Dr. Truong Gia Binh, FPT Chairman, stated: 'To accompany Vietnam's new era of advancement, the healthcare sector must achieve breakthroughs in three areas: regulation, innovation, and public–private collaboration. We must shift from restrictive thinking to viewing regulation as a driver of national competitiveness, ensuring faster access to new medicines, like in the U.S. or Japan. Vietnam can become a hub for AI-powered clinical trials and drug development, leveraging its strong tech talent with 1 million IT workers, aiming for half to be AI-proficient. Public–private partnerships must connect hospitals, pharmaceutical firms, and healthcare professionals through shared data platforms. Just as Vietnam rose to global prominence in software, it can now aim to lead in innovative pharmaceuticals - one of the world's most advanced industries.'
AI in Pharma: A Global Trend and an Opportunity for Vietnam
Recent data shows 80% of pharma professionals use AI for drug discovery, with 95% of companies investing in it; and AI can cut drug development time from 5-6 years to one. In clinical trials, AI can reduce costs by 70% and timelines by 80%.
Mr. Hoang Viet Anh, FPT Digital Chairman and FPT Telecom Chairman, FPT Corporation, underscored: 'AI and GenAI are transforming the pharmaceutical industry, with key benefits including accelerating new drug development and enhancing clinical trials across the value chain.' He also called this a key moment for digital transformation, outlining an AI roadmap for Vietnam's pharmaceutical sector through 2028. Plans include a centralized data system and AI lab pilots in 2025, blockchain trials in 2026 to fight counterfeit drugs, and a 20% reduction in drug trial time by 2027, aiming to become ASEAN's leading AI hub by 2028.
Achieving Resolution 57 and National Goals for Healthcare Breakthroughs
As Vietnam pursues its 2045 high-income vision, healthcare emerges as a key pillar for quality of life, social security, and sustainable growth. The round table discussing critical factors to achieve Resolution 57 objectives emphasized three key messages. Firstly, AI and big data drive healthcare innovation, enabling faster drug development and personalized care. Secondly, bold legal and institutional reforms are essential to match tech advances, including streamlined approvals and flexible data regulations. Lastly, strong public-private collaboration is vital to build a sustainable innovation ecosystem connecting tech firms, hospitals, research institutes, and startups.
Mr. Vu Anh Tu, FPT Chief Technology Officer, commented: 'AI is set to transform healthcare, and by creating a centralized health data infrastructure and leveraging AI and data analysis for new drug trials, Vietnam can establish advanced clinical research centers, shorten timelines, reduce costs, and expand public access to new medicines. Technology can also enable new healthcare delivery models like telemedicine hospitals to improve primary healthcare and expand public access.'
He further stated: 'FPT is ready to collaborate with startups, major enterprises, and global AI research institutions to address key challenges through AI. This approach will mobilize domestic and international resources to drive breakthroughs in this new era.'
About Pharma Group
Founded in 1998, Pharma Group represents the innovative pharmaceutical industry in Vietnam, comprising 20 member companies from Europe, the United States, and Japan. These companies share a mission to ensure timely and sustainable access to high-quality, safe, and innovative medicines for Vietnamese patients.
Pharma Group operates under the European Chamber of Commerce in Vietnam (EuroCham) and is a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). It works closely with policymakers and healthcare stakeholders in Vietnam and globally to advance sustainable health policies and initiatives, reduce the time to patient access, and build a favorable and attractive investment environment.
About FPT Corporation
FPT Corporation is Vietnam's leading technology group, pioneering digital transformation and leading in technology and telecommunications solutions and services. FPT supports clients in over 30 countries and territories in achieving their business development strategies through technology.
In the healthcare sector, FPT is committed to building a remote healthcare platform and a comprehensive digital medical ecosystem that delivers fast, convenient, and integrated services for regulators, medical institutions, pharmaceutical companies, pharmacy networks, and the public. Leveraging over a decade of AI research and development, FPT actively integrates AI technologies to enhance healthcare quality and expand access to personalized medical services, particularly through telemedicine and real-time patient health monitoring. In pharmaceuticals, FPT advances the sector by digitizing R&D processes, deploying Advanced Pharmacy Omni-Channel Systems, and developing comprehensive drug management platforms connecting patients, doctors, and pharmacies through electronic medical records. Prominent clients include Long Chau Pharmacy, Hitachi Medical Devices, Olympus, MedAdvisor, Zuellig Pharma, and BrightInsight.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250606137635/en/
CONTACT: Media Contact
Mai Duong (Ms.)
FPT Corporation
FPT Software PR Manager
[email protected]
KEYWORD: VIET NAM SOUTHEAST ASIA ASIA PACIFIC
INDUSTRY KEYWORD: TECHNOLOGY CLINICAL TRIALS HEALTH TECHNOLOGY TELEMEDICINE/VIRTUAL MEDICINE SOFTWARE HEALTH PHARMACEUTICAL DATA MANAGEMENT ARTIFICIAL INTELLIGENCE
SOURCE: FPT Corporation
Copyright Business Wire 2025.
PUB: 06/06/2025 07:13 AM/DISC: 06/06/2025 07:12 AM
http://www.businesswire.com/news/home/20250606137635/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@
Yahoo
5 hours ago
- Yahoo
Montréal and Toronto have some of the worst air quality in the world due to wildfire smoke: How to protect yourself, according to an expert
Toronto and Montreal's air quality is on par with some of the worst in the world due to drifting wildfire smoke. While fires continue to burn in Western Canada, wind has carried smoke from the fires to Ontario, Quebec and areas in the U.S. like Nebraska, Michigan and Wisconsin. The impact of wildfire smoke is so severe, Environment Canada issued air quality statements for the Greater Toronto Area (GTA) and Montréal Island Area. As of 12:25 p.m. EST., IQAir, a Swiss technology company, ranked Montreal as the city with the worst air quality in the world. Toronto came in third place, behind Santiago. Environment Canada is encouraging people, especially the elderly, pregnant people, children and people with chronic health conditions, to avoid spending time outdoors whenever possible. As of June 6, the Canadian Interagency Forest Fire Centre reported 212 active fires in Canada, with 91 considered out of control. Mandatory evacuation orders were issued for parts of Alberta and Saskatchewan due to poor visibility and air quality due to smoke. Manitoba's state of emergency required residents of several communities to evacuate due to air quality and lack of power. This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Contact a qualified medical professional before engaging in any physical activity, or making any changes to your diet, medication or lifestyle. Wildfire smoke isn't just contained to affected areas. Environment Canada has issued a weather alert for parts of Ontario due to poor air quality that may cause people to experience symptoms like cough, headaches as well as nose and throat irritation. The Weather Channel in the U.S. reported wildfire smoke from Canada is visible as far as the Gulf Coast. Winds have caused smoke to impact air quality in states like Minnesota, Iowa, Wisconsin, Michigan as well as North and South Dakota. As the wildfire season kicks off, ways to protect ourselves from smoke are top-of-mind for many. Yahoo Canada previously spoke to a top respirologist in Toronto, who weighed in on the impact of smoke on our lungs, and what to do to stay safe. Read on for everything you need to know. Dr. John Granton, a respirologist at the Toronto General Hospital (University Health Network), told Yahoo Canada wildfires cause air pollution that can have a far-reaching effect on human health. Small air pollutant particles in the smoke, called the PM2.5 particles, are "where a lot of the toxic stuff lives," Granton explained. "That's not filtered by your upper airway, that gets access to your lower airway and into your bloodstream even — and that's where the danger lies. "That can cause asthma attacks, can cause heart attacks, can contribute to hospitalizations and has long-term health outcomes." Even just the smell could cause problems to some, he said. "Being in smog all day long, the smell bothers people; it can cause irritation of the upper airway, some of the larger particles can cause irritation, and cause symptoms. People [who] have chest symptoms or asthma, it can make them feel worse." Granton said smoke isn't easy to escape, but there are some things people can do try and stay safe. According to Granton, "there's not a lot of data to support the health benefits of masking" when it comes to safety from wildfire smoke. But, he said there is research looking into the effectiveness of filters. "Cloth masks or scarves and things are not effective at all," the doctor claimed. But, surgical masks and N95 filter masks "tend to filter those smaller particles," he added, "apparently some of those masks are effective." Granton said "they're not going to filter the gases," though, and there are studies that question whether masks that aren't properly fitted would actually help in the real world. "Whether or not that has a direct health benefit is speculative right now," Granton explained. However, he said it "may be reasonable" for those who have underlying health conditions and those who have to be in the hotspots of the pollution to wear one. "If you have to be outdoors and doing things, then wearing that sort of mask to protect you would be sensible." Though filtration masks could aid in protecting your lungs from smoke, the number one recommendation from experts is to stay indoors. According to Health Canada, the following measures should also be taken: Reduce sources of indoor air pollution (smoking, vacuuming, burning candles, wood stoves) Prevent infiltration of outside air (seal windows, instal a high-quality air filter, set HVAC system to recirculation mode, limit use of exhaust fans when not cooking) Have a functioning CO alarm Use a portable air purifier and air conditioning Granton echoed this advice. "Most people recommend staying indoors as much as possible and not exercising or doing things outside," he reiterated. Room Size: 47 ft2 Tobacco Smoke CADR: 30 Dust CADR: 41 PM2.5 CADR: 35 Pollen CADR: 52 Volts / Frequency: 120V / 60Hz Room Size: 140 ft2 Tobacco Smoke CADR: 90 Dust CADR: 101 PM2.5 CADR: 95 Pollen CADR: 119 Volts / Frequency: 120V / 60Hz Room Size: 170 ft2 Tobacco Smoke CADR: 110 Dust CADR: 120 Pollen CADR: 130 Volts / Frequency: 120V / 60Hz Room Size: 206 ft2 Tobacco Smoke CADR: 133 Dust CADR: 141 Pollen CADR: 145 Volts / Frequency: 120V / 60Hz Room Size: 200 ft2 Tobacco Smoke CADR: 132 Dust CADR: 130 Pollen CADR: 152 Volts / Frequency: 120V / 60Hz Room Size: 358 ft2 Tobacco Smoke CADR: 231 Dust CADR: 240 PM2.5 CADR: 236 Pollen CADR: 259 Volts / Frequency: 120V / 60Hz
